Dermatitis

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Severe disease, male sex, family history and prenatal factors were significantly associated with an increased risk for atopic march progression in infants with atopic dermatitis, according to a study.

The year 2024 was important for skin disorders with many innovations and breakthroughs.

The FDA has cleared the investigational new drug application for STAR-0310 as a potential treatment for atopic dermatitis and other diseases, Astria Therapeutics announced in a press release.

BOSTON — Daily tapinarof cream 1% improved weekly itch outcomes and sleep in patients with atopic dermatitis and pruritus, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Roflumilast cream improved signs and symptoms of atopic dermatitis, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.

Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.